Lung highlights from ESMO 2018

Erlotinib for neoadjuvant treatment of EGFR NSCLC

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC

20 year followup on high-dose chemo with HSCT in high-risk breast cancer

Opportunities for biosimilars in practice and education

VALENTINO: Maintenance therapy in advanced CRC

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Ceritinib and ribociclib in ALK-positive NSCLC

Cemiplimab in patients with hepatocellular carcinoma

Updates from the EMBRACA trial for advanced breast cancer

Comment on the Every Woman Study